CurrentEndo
Get Weekly

CurrentEndo coverage · page 50 of 55

Diabetes, Obesity and Metabolism

Briefs 1,961–2,000 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Diabetes remission in drug‐naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study

    Cohort studyT2D & other

  2. Diabetes Obes Metab

    All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes

    Cohort studyT2D & other

  3. Diabetes Obes Metab

    Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial

    Secondary analysisT2D & other

  4. Diabetes Obes Metab

    Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function

    Secondary analysisT2D & other

  5. Diabetes Obes Metab

    Association between glycaemia risk index ( GRI ) and diabetic retinopathy in type 2 diabetes: A cohort study

    Cohort studyT2D & other

  6. Diabetes Obes Metab

    Association of socioeconomic deprivation with sleep health in patients with type 2 diabetes

    Cross-sectional studyT2D & other

  7. Diabetes Obes Metab

    Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants

    Randomized controlled trialT2D & other

  8. Diabetes Obes Metab

    Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

    Research articleObesity

  9. Diabetes Obes Metab

    Trends and disparities in telehealth use among Louisiana Medicaid beneficiaries with type 2 diabetes

    Cohort studyT2D & other

  10. Diabetes Obes Metab

    Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study

    Randomized controlled trialT2D & other

  11. Diabetes Obes Metab

    Trajectories of fasting glucose and glycated haemoglobin in obese and non‐obese incident diabetes: Results from two large cohort studies

    Cohort studyT2D & other

  12. Diabetes Obes Metab

    Nutritional strategies for correcting low glucose values in patients with postbariatric hypoglycaemia: A randomized controlled three‐arm crossover trial

    Randomized controlled trialObesity

  13. Diabetes Obes Metab

    A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States

    Diagnostic or prognostic studyT2D & other

  14. Diabetes Obes Metab

    Cost‐utility of real‐time continuous glucose monitoring versus self‐monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark

    Research articleTechnology

  15. Diabetes Obes Metab

    Crosstalk between genetic variability of adiponectin and leptin, glucose‐insulin system and subclinical atherosclerosis in patients with newly diagnosed type 2 diabetes. The Verona Newly Diagnosed Type 2 Diabetes Study 14

    Cross-sectional studyT2D & other

  16. Diabetes Obes Metab

    Serum uric acid lowering and effects of sodium‐glucose cotransporter‐2 inhibitors on gout: A meta‐analysis and meta‐regression of randomized controlled trials

    Meta-analysisT2D & other

  17. Diabetes Obes Metab

    Real‐world study of ethnic differences in glycaemic control and clinical characteristics among insulin‐naïve people with type 2 diabetes initiating biphasic insulin aspart 30/70: A retrospective, observational cohort study in England

    Cohort studyT2D & other

  18. Diabetes Obes Metab

    Severe hypoglycaemia in adults presenting to a hospital emergency department: Clinical characteristics, comorbidities, and mortality outcomes

    Cohort studyComplications

  19. Diabetes Obes Metab

    Safety/tolerability, efficacy and pharmacokinetics of 600‐μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m 2 or higher: A phase I, randomized, double‐blind, placebo‐controlled study

    Randomized controlled trialT2D & other

  20. Diabetes Obes Metab

    Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study)

    Cohort studyT2D & other

  21. Diabetes Obes Metab

    Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes

    Randomized controlled trialT2D & other

  22. Diabetes Obes Metab

    Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long‐acting glucagon analogue HM15136 in overweight and obese patients with co‐morbidities

    Randomized controlled trialObesity

  23. Diabetes Obes Metab

    Effects of dietary quality, physical activity and weight loss on glucose homeostasis in persons with and without prediabetes in the PREMIER trial

    Secondary analysisT2D & other

  24. Diabetes Obes Metab

    Neighbourhood‐level social deprivation and the risk of recurrent heart failure hospitalizations in type 2 diabetes

    Cohort studyT2D & other

  25. Diabetes Obes Metab

    Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics

    Meta-analysisT2D & other

  26. Diabetes Obes Metab

    Respiratory effort during sleep and the rate of prevalent type 2 diabetes in obstructive sleep apnoea

    Cross-sectional studyT2D & other

  27. Diabetes Obes Metab

    Risk of breakthrough SARS‐CoV‐2 infection and clinical outcomes among vaccinated patients with type 2 diabetes

    Cohort studyT2D & other

  28. Diabetes Obes Metab

    Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial

    Randomized controlled trialObesity

  29. Diabetes Obes Metab

    Impact of pre‐existing type 2 diabetes with and without cardiovascular disease on patients with COVID ‐19

    Cohort studyT2D & other

  30. Diabetes Obes Metab

    Diabetes, fasting blood glucose and the efficacy of remote ischaemic conditioning: A secondary analysis of the RICAMIS trial

    Secondary analysisT2D & other

  31. Diabetes Obes Metab

    Weight change and risk of obesity‐related complications: A retrospective population‐based cohort study of a UK primary care database

    Cohort studyObesity

  32. Diabetes Obes Metab

    Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease

    Randomized controlled trialT2D & other

  33. Diabetes Obes Metab

    Metabolic bariatric surgery as a therapeutic option for patients with type 2 diabetes: A meta‐analysis and network meta‐analysis of randomized controlled trials

    Meta-analysisT2D & other

  34. Diabetes Obes Metab

    Perceptions, behaviours and potential barriers to effective obesity care. Results from the ACTION‐DK study

    Cross-sectional studyObesity

  35. Diabetes Obes Metab

    Acute pharmacodynamic responses to exenatide: Drug‐induced increases in insulin secretion and glucose effectiveness

    Randomized controlled trialT2D & other

  36. Diabetes Obes Metab

    Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes

    Randomized controlled trialT2D & other

  37. Diabetes Obes Metab

    Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta‐analysis of randomized controlled trials

    Meta-analysisObesity

  38. Diabetes Obes Metab

    Glycaemic patterns of male professional athletes with type 1 diabetes during exercise, recovery and sleep: Retrospective, observational study over an entire competitive season

    Cohort studyT1D

  39. Diabetes Obes Metab

    Advancing therapy in people with suboptimally controlled basal insulin‐treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries

    Randomized controlled trialT2D & other

  40. Diabetes Obes Metab

    Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID ‐19 patients: Comparison with influenza and pre‐pandemic data

    Cohort studyT1D

All 2,200 Briefs in ExploreShowing Briefs 1,961–2,000 of 2,200, newest first